Techlicious

Review of the Quell 2.0 Wearable Pain Relief Device

The Quell 2.0 can’t assess or measure pain, so it needs you to do it, selecting from 0-10 the level of pain you felt generally, when active, while sleeping and how it affected your mood. Using those ...
Business Wire

NeuroMetrix’ Quell Device Makes Second Appearance at American Society of Regional Anesthesia’s Annual Pain Medicine Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that Quell ® Wearable Pain Relief Technology™ will be featured for the second year in a row at the American ...
Nasdaq

NeuroMetrix Announces Submission of FDA De Novo Request for Treatment of Fibromyalgia Symptoms with the Quell® Wearable Neuromodulation Device

WOBURN, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has submitted a De Novo request to the U.S. Food and Drug Administration (FDA) for Quell as a ...
Business Insider

NeuroMetrix Reports Results of Large Clinical Study of Quell Wearable Pain Relief

WALTHAM, Mass., April 10, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported publication of results from a clinical study of Quell® in the Journal of Pain Research. The paper is ...
Business Insider

NeuroMetrix Reports Presentation of Clinical and Scientific Data on Quell Wearable Pain Relief Technology at PAINWeek 2018 National Conference

WALTHAM, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported that it will present three scientific posters at the upcoming PAINWeek 2018 National Pain Conference ...
CNN

NeuroMetrix to Target Chronic Knee Pain with Quell® 2.0 Wearable Pain Relief Device

WOBURN, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has launched a marketing initiative focusing on chronic knee pain. This effort includes direct ...
FOX59 News

NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting

WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39 th Annual Meeting on March 23 - 26 in Ft.
Seeking Alpha

electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness

Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ECOR,” “electroCore,” or the “Company”) ...
Nasdaq

NeuroMetrix Announces That Top-Line Results from a Randomized Controlled Trial of Quell® for Treatment of Fibromyalgia to be Presented at Two Upcoming Pain Medicine Conferences

In the intention-to-treat (ITT) population, the treatment difference in the Patient Global Impression of Change (PGIC, primary endpoint) was not significant (sham 3.24 ± 0.26, active 3.58 ± 0.25, ...